Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-AGILE: Neoadjuvant Abemaciclib and Giredestrant in Early Breast Cancer
NCT06259929Phase 2Recruiting
- Sponsor
- Fondazione Oncotech
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, giredestrant in breast cancer, sponsored by Fondazione Oncotech. Started Jan 2025; status: recruiting.
02
Drugs
abemaciclibgiredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06259929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259929.